ClinVar Miner

Submissions for variant NM_006610.4(MASP2):c.359A>G (p.Asp120Gly) (rs72550870)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Division of Genomic Diagnostics,The Children's Hospital of Philadelphia RCV000239142 SCV000297214 benign not specified 2015-11-11 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000005520 SCV000347217 likely pathogenic MASP2 deficiency 2017-10-20 criteria provided, single submitter clinical testing The MASP2 c.359A>G (p.Asp120Gly) missense variant has been reported in two studies in which it is described in a homozygous state in two individuals with recurrent infections and low serum MASP2 levels (Stengaard-Pedersen et al. 2003; Cedzynski et al. 2004). Additional family members who were heterozygous for the variant were found to have low serum MASP2 concentrations but no clinical symptoms. The p.Asp120Gly variant has also been investigated in healthy unrelated individuals from different populations. Four individuals were found to carry the p.Asp120Gly variant in a homozygous state and have MASP2 deficiency but show no clinical symptoms (García-Laorden et al. 2006; Olszowski et al. 2014; Sokolowska et al. 2015). Functional studies by Stengaard-Pedersen et al. (2003) and Thiel et al. (2009) demonstrated that the p.Asp120Gly variant had a reduced capacity to activate complement through the MBL-initiated classical pathway. While the allele frequency for the p.Asp120Gly variant appears to be high at 0.0479 in the European (Finnish) population of the Exome Aggregation Consortium, studies have shown an over-representation of this variant in individuals with low levels of MASP2 as compared to controls. Many individuals who carry variants classified as pathogenic in MASP2 never experience clinical symptoms, and therefore this variant is thought to confer a mildly elevated risk for infection and inflammatory diseases. Based on the evidence, the p.Asp120Gly variant is classified as likely pathogenic for MASP2 deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
OMIM RCV000005520 SCV000025702 pathogenic MASP2 deficiency 2003-08-07 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.